Symposium 18: Immune dysregulation in cardiovascular disease - from novel mechanisms to therapeutic targeting
Tracks
Track 2
Thursday, July 16, 2026 |
11:15 AM - 1:15 PM |
Details
A substantial body of research has highlighted the role of inflammation in all stages of atherosclerosis. Advances in multiomics techniques have unveiled the intricate complexity of immune cells across various cardiovascular diseases (CVD). Additionally, large-scale clinical trials have validated the inflammatory hypothesis in humans, providing solid evidence that targeting inflammation is an effective strategy for treating CVD. This research led to a significant milestone in June 2023, when the FDA approved colchicine as the first anti-inflammatory treatment for the secondary prevention of CVD.
The goal of this symposium is to offer a comprehensive overview of the latest knowledge on immune mechanisms in CVD and their potential as therapeutic targets. To achieve this, we have invited internationally renowned scientists to share their insights.
We propose hosting this symposium on behalf of the IUPHAR Immunopharmacology Committee, aimed at engaging scientists and clinicians interested in the intersection of pharmacology, immunology, and cardiovascular science.
Speaker
Prof Pasquale Maffia
University Of Glasgow
Immune Dysregulation in Cardiovascular Disease - From Novel Mechanisms to Therapeutic Targeting
Biography
I am a Professor of Cardiovascular Immunology at the University of Glasgow (UK), based within the School of Infection & Immunity. I also serve as the School’s International Lead and Director of the ARUA/Guild Africa-Europe Centre of Excellence in Non-Communicable Diseases and Multimorbidity. Additionally, I hold an adjunct appointment as Professor of Pharmacology at the University of Naples Federico II (Italy). I am an elected Fellow of the Royal Society of Biology, the British Pharmacological Society, and the European Society of Cardiology.
My leadership roles include serving as Vice-President and Chair of the Engagement Committee of the British Pharmacological Society (BPS); Chair of the Immunopharmacology Committee and Vice-Chair of the Basic and Translational Section of the International Union of Basic and Clinical Pharmacology (IUPHAR); and Chair of the Translational Research Medical Review Panel for Heart Research UK (HRUK). I am also a Nucleus Member of the European Society of Cardiology (ESC) Working Groups on Atherosclerosis & Vascular Biology and Cellular Biology of the Heart, and a member of the Executive Committee of the British Atherosclerosis Society (BAS). Additionally, I serve as Vice-Chair of the Immunotherapy Committee of the International Union of Immunological Societies (IUIS), a member of the Translational Clinical Studies (TCS) Grant Panel for the Chief Scientist Office (CSO), and a collaborator on the Global Burden of Disease (GBD) project. In the editorial sphere, I am Deputy Editor of Cardiovascular Research and Associate Editor of Pharmacological Research.
My research is driven by a longstanding interest in the role of the immune system in cardiovascular diseases. I conduct both basic and clinical investigations aimed at elucidating and targeting immune and inflammatory mechanisms involved in atherosclerosis, hypertension, and heart failure, with a dedicated focus on cardiovascular disease in Africa. I have authored over 140 peer-reviewed publications in leading journals such as Nature Genetics, Nature Reviews Immunology, Nature Reviews Cardiology, The Lancet Global Health, Immunity, European Heart Journal, Circulation, and Circulation Research.
Session chair
Pasquale Maffia
University Of Glasgow
Jonathan Noonan
Baker Heart and Diabetes Institute & Baker Department of Cardiometabolic Health, University of Melbourne
